Suppr超能文献

放射性标记去纤苷在大鼠口服或静脉给药后的药代动力学研究。

Study on pharmacokinetics of radioactive labelled defibrotide after oral or intravenous administration in rats.

作者信息

Fisher J, Holland T K, Pescador R, Porta R, Ferro L

机构信息

Inveresk Research International, Tranent, Scotland.

出版信息

Thromb Res. 1996 Jan 1;81(1):55-63. doi: 10.1016/0049-3848(95)00213-8.

Abstract

Defibrotide (D) was labelled with 125I or with 32P. The radiolabelled compounds ([125I]-Defibrotide ([125I]-D), [32P]-Defibrotide ([32P]-D) retained the same profibrinolytic activity, in vitro, as the parent drug, suggesting that the labelling procedures had not modified the pharmacological properties of D and hence that its chemical structure was not affected significantly. After single intravenous or oral administration of [125I]-D or [32P]-D the pharmacokinetic parameters for the two labels were generally in good agreement (75%). t 1/2 alpha was in the range of minutes while t 1/2 beta was in the range of hours. Bioavailability, following single oral administration of [125I]-D or [32P]-D, was in the range of 58-70%. These data suggest that D, in spite of its macromolecular nature, is absorbed, after oral administration, fairly well.

摘要

去纤苷(D)用125I或32P进行标记。放射性标记化合物([125I] - 去纤苷([125I] - D),[32P] - 去纤苷([32P] - D))在体外保留了与母体药物相同的促纤溶活性,这表明标记过程未改变D的药理特性,因此其化学结构未受到显著影响。单次静脉注射或口服[125I] - D或[32P] - D后,两种标记物的药代动力学参数总体上吻合良好(75%)。t 1/2α在数分钟范围内,而t 1/2β在数小时范围内。单次口服[125I] - D或[32P] - D后的生物利用度在58 - 70%范围内。这些数据表明,D尽管具有大分子性质,但口服后吸收相当良好。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验